Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$158.24 USD

158.24
2,305,872

-0.38 (-0.24%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $158.22 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 246)

Industry: Medical - Dental Supplies

Zacks News

Maharathi Basu headshot

5 Broker-Loved Stocks to Keep an Eye on Amid Trade Tensions

Investors should monitor stocks like Cardinal Health, DXC Technology, Cross Country Healthcare, Avnet and Asbury for high returns.

Zacks Equity Research

ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?

RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.

Zacks Equity Research

SYK Stock Gains on Launch of Hands-Free Device: Sync Badge

Stryker's Sunc Badge is a Hands-free, wearable communication device that will support care team members with fast and reliable collaboration. It is likely to help offset the ongoing nurse shortage.

Zacks Equity Research

VEEV Stock Falls Despite Latest Announcement to Enable AI Innovation

Veeva Systems aims to enable advanced automation, including AI, for the life sciences industry via innovative technology and deep applications on the Veeva Vault Platform.

Zacks Equity Research

BSX Stock Set to Gain From the New Agreement to Acquire SoniVie Ltd.

Boston Scientific inks a deal to acquire the remaining 90% stake in SoniVie Ltd.

Zacks Equity Research

TECH Joins Forces With Oxford Nanopore Technologies: Stock to Gain?

Bio-Techne's Asuragen brand inks a partnership with Oxford Nanopore Technologies to launch research-use-only AmplideX Nanopore Carrier Plus Kit.

Zacks Equity Research

Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?

Smart Beta ETF report for ONEV

Zacks Equity Research

Quest Diagnostics Stock Jumps 38% in a Year: What's Behind the Surge?

DGX outperforms the industry and the S&P 500 composite's gain in the past year, driven by strong core performance and contributions from acquisitions.

Zacks Equity Research

Integra Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Stock Up

IART delivers better-than-expected earnings in the fourth quarter of 2024.

Zacks Equity Research

AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises

Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.

Zacks Equity Research

SOLV Stock Down Despite Q4 Earnings & Revenues Beat Estimates

Solventum's fourth-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.

Zacks Equity Research

TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates

TMDX's fourth-quarter earnings depict strength in the company's net product revenues and services revenues. A rise in operating income bodes well for the stock.

Zacks Equity Research

OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands

The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.

Zacks Equity Research

Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail

Penumbra is still in the early stages of its journey to bring the company's proprietary thrombectomy technologies to patients in the United States and around internationally.

Zacks Equity Research

Alcon Stock Gains From Innovation Despite Macroeconomic Troubles

Within Vision Care, ALC is registering solid growth, banking on strong sales of its contact lenses and ocular health products.

Zacks Equity Research

Teleflex Stock Rises on Q4 Earnings Beat, Gross Margin Crashes

TFX benefits from a diversified product portfolio in the fourth quarter of 2024, with strength in the Surgical and Interventional segments.

Zacks Equity Research

Is it Apt to Retain Omnicell Stock in Your Portfolio Now?

OMCL stays on investors' radar due to its impressive long-term growth initiative.

Zacks Equity Research

Chemed Q4 Earnings & Revenues Top, Stock Climbs, Margins Contract

CHE's earnings and revenues beat estimates in the fourth quarter of 2024.

Zacks Equity Research

Is PAHC Stock a Smart Addition to Your Portfolio Right Now?

Phibro's robust performance in the Animal Health business and prospects in the emerging markets are highly encouraging.

Zacks Equity Research

XRAY Q4 Earnings & Revenues Miss Estimates, Gross Margin Down

DENTSPLY SIRONA's fourth-quarter results showcase dismal segmental performance with declining adjusted operating income.

Zacks Equity Research

AVNS Stock Gains Post Q4 Earnings & Revenue Beat, Margins Contract

Strength in Avanos' Digestive Health segment drives its fourth-quarter 2024 performance despite global macroeconomic challenges.

Zacks Equity Research

TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss

Tandem Diabetes' Q4 top and bottom lines lag their respective estimate. However, the company experiences strong sales growth both in and outside the United States.

Zacks Equity Research

EYE Q4 Loss Narrower Than Expected, Margins Rise, Stock Surges

Continued strength in Managed Care aids National Vision's fourth-quarter 2024 performance.

Zacks Equity Research

Zacks.com featured highlights Prairie Operating, Intuit and Cardinal Health

Prairie Operating, Intuit and Cardinal Health have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

Watch These 3 Stocks for Solid Earnings Acceleration

Prairie Operating, Intuit and Cardinal Health are exhibiting strong earnings acceleration.